PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.98%
Negative revenue growth while Drug Manufacturers - Specialty & Generic median is -8.58%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-5.67%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is -5.67%. Seth Klarman would suspect poor product pricing or inefficient production.
-77.54%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 21.23%. Seth Klarman would check if external or internal factors caused the decline.
-77.54%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is -10.37%. Seth Klarman would check if structural or cyclical issues are at play.
-23.37%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is -11.00%. Seth Klarman would investigate factors dragging net income down.
-11.75%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is -11.75%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-11.75%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is -11.75%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
10.30%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
10.30%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-213.44%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is -35.14%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-293.67%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is -60.44%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
-49.02%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 9.46%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-38.88%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-73.69%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 63.85%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
63.22%
5Y OCF/share growth near Drug Manufacturers - Specialty & Generic median. Charlie Munger might attribute it to standard sector conditions for mid-term OCF expansions.
80.56%
3Y OCF/share growth 1.25-1.5x Drug Manufacturers - Specialty & Generic median. Mohnish Pabrai would confirm if cost advantage or brand strength explains near-term outperformance.
-1805.63%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 52.82%. Seth Klarman might see a fundamental problem if peers maintain growth.
-176.55%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 51.24%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
51.73%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 33.20%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
9259.09%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 26.55% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-35.28%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is -17.30%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-58.67%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is -17.74%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.30%
AR growth of 2.30% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
4.84%
Inventory growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
-1.69%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-8.28%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -1.04%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
0.29%
Slightly rising debt while Drug Manufacturers - Specialty & Generic median is deleveraging. Peter Lynch wonders if the firm lags behind peers in risk control or invests in more expansions.
-73.35%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-19.29%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.